Wharton's jelly and osteoarthritis of the knee.

IF 6.7 2区医学 Q1 Medicine

British medical bulletin Pub Date : 2024-03-13 DOI:10.1093/bmb/ldad030

Adarsh Aratikatla, Nicola Maffulli, Manu Gupta, Ishana A Potti, Anish G Potty, Ashim Gupta

{"title":"Wharton's jelly and osteoarthritis of the knee.","authors":"Adarsh Aratikatla, Nicola Maffulli, Manu Gupta, Ishana A Potti, Anish G Potty, Ashim Gupta","doi":"10.1093/bmb/ldad030","DOIUrl":null,"url":null,"abstract":"Introduction: The existing treatment modalities for knee osteoarthritis (OA) do not actually address the pathology. Biological therapies, including those using material derived from perinatal tissues, represent a ground-breaking approach to alleviating the symptoms of OA of the knee.Source of data: Current scientific literature published in PubMed (MEDLINE), Embase and Scopus databases. Trials registered in various clinical trial databases.Areas of agreement: Perinatal tissues including Wharton's jelly (WJ) and associated mesenchymal stem cells (MSCs) can be used for the management of knee OA.Areas of controversy: The efficacy of WJ and associated MSCs in the management of knee OA is still controversial.Growing points: The use of WJ and associated MSCs in the management of knee OA is safe and appears to be effective.Areas timely for developing research: The present published evidence suggests that WJ tissue and associated MSCs offer an encouraging alternative for the management of knee OA. The published in vitro, preclinical and clinical investigations demonstrate the therapeutic potential of WJ and promote further research in this field to provide symptomatic relief to patients suffering from OA, aiming also to regenerate the osteoarthritic hyaline cartilage, with disease-modifying effects. Future adequately powered randomized controlled trials should be undertaken to establish whether WJ is helpful in the management of OA of the knee.","PeriodicalId":9280,"journal":{"name":"British medical bulletin","volume":" ","pages":"13-31"},"PeriodicalIF":6.7000,"publicationDate":"2024-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10993459/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"British medical bulletin","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/bmb/ldad030","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The existing treatment modalities for knee osteoarthritis (OA) do not actually address the pathology. Biological therapies, including those using material derived from perinatal tissues, represent a ground-breaking approach to alleviating the symptoms of OA of the knee.

Source of data: Current scientific literature published in PubMed (MEDLINE), Embase and Scopus databases. Trials registered in various clinical trial databases.

Areas of agreement: Perinatal tissues including Wharton's jelly (WJ) and associated mesenchymal stem cells (MSCs) can be used for the management of knee OA.

Areas of controversy: The efficacy of WJ and associated MSCs in the management of knee OA is still controversial.

Growing points: The use of WJ and associated MSCs in the management of knee OA is safe and appears to be effective.

Areas timely for developing research: The present published evidence suggests that WJ tissue and associated MSCs offer an encouraging alternative for the management of knee OA. The published in vitro, preclinical and clinical investigations demonstrate the therapeutic potential of WJ and promote further research in this field to provide symptomatic relief to patients suffering from OA, aiming also to regenerate the osteoarthritic hyaline cartilage, with disease-modifying effects. Future adequately powered randomized controlled trials should be undertaken to establish whether WJ is helpful in the management of OA of the knee.

查看原文本刊更多论文

沃顿果冻与膝关节骨性关节炎

导言：现有的膝关节骨关节炎（OA）治疗方法并不能真正解决病理问题。生物疗法，包括使用从围产期组织中提取的材料的疗法，是缓解膝关节 OA 症状的突破性方法：在 PubMed (MEDLINE)、Embase 和 Scopus 数据库中发表的最新科学文献。在各种临床试验数据库中注册的试验：围产期组织，包括沃顿果冻（WJ）和相关间充质干细胞（MSCs）可用于治疗膝关节OA：WJ和相关间充质干细胞在膝关节OA治疗中的疗效仍存在争议：成长点：使用 WJ 和相关间充质干细胞治疗膝关节 OA 是安全且有效的：目前已发表的证据表明，WJ组织和相关间充质干细胞为治疗膝关节OA提供了一种令人鼓舞的选择。已发表的体外、临床前和临床研究证明了 WJ 的治疗潜力，并促进了这一领域的进一步研究，以缓解 OA 患者的症状，同时也旨在再生骨关节炎透明软骨，达到疾病调节的效果。今后应进行充分的随机对照试验，以确定 WJ 是否有助于膝关节 OA 的治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British medical bulletin 医学-医学：内科

CiteScore

13.10

自引率

1.50%

发文量

审稿时长

>12 weeks

期刊介绍： British Medical Bulletin is a multidisciplinary publication, which comprises high quality reviews aimed at generalist physicians, junior doctors, and medical students in both developed and developing countries. Its key aims are to provide interpretations of growing points in medicine by trusted experts in the field, and to assist practitioners in incorporating not just evidence but new conceptual ways of thinking into their practice.